Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $117.6 million.

  • Trinity Biotech's Total Non-Current Liabilities rose 2006.53% to $117.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $117.6 million, marking a year-over-year increase of 2006.53%. This contributed to the annual value of $106.4 million for FY2024, which is 5563.65% up from last year.
  • According to the latest figures from Q2 2025, Trinity Biotech's Total Non-Current Liabilities is $117.6 million, which was up 2006.53% from $106.4 million recorded in Q4 2024.
  • In the past 5 years, Trinity Biotech's Total Non-Current Liabilities ranged from a high of $117.6 million in Q2 2025 and a low of $18.7 million during Q4 2021
  • For the 5-year period, Trinity Biotech's Total Non-Current Liabilities averaged around $75.5 million, with its median value being $77.4 million (2022).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 8226.28% in 2021, then surged by 31094.38% in 2022.
  • Trinity Biotech's Total Non-Current Liabilities (Quarter) stood at $18.7 million in 2021, then soared by 310.94% to $76.9 million in 2022, then dropped by 11.17% to $68.3 million in 2023, then soared by 55.64% to $106.4 million in 2024, then rose by 10.59% to $117.6 million in 2025.
  • Its last three reported values are $117.6 million in Q2 2025, $106.4 million for Q4 2024, and $95.7 million during Q3 2024.